Skip to main content
. Author manuscript; available in PMC: 2020 Nov 1.
Published in final edited form as: Int J Psychophysiol. 2019 May 23;145:15–22. doi: 10.1016/j.ijpsycho.2019.05.009

Table 1.

Participant Characteristics

Gender and Diagnoses
EPP Control
Sample size 34 19
Female/Male 7/24 14/5
Diagnosis, n (%)
 Psychosis disorder NOS 4 (13%) -
 Schizoaffective 6 (19%) -
 Schizophrenia 17 (55%) -
 Schizophreniform 4 (13%) -
M (SD) M (SD)
EPP Control
Age, years 22.0 (4.3) 22.9 (3.6)
BACS composite score 29.9 (14.2) 48.8 (11.7)**
Illness Duration, years 2.01 (1.33) -
CPZ Lifetime Exposure, grams 139.6 (173.0) -
PANSS total scoreb 53.7 (13.6) -
PANSS cognitive/disorganized factor 12.6 (3.7) -
PANSS negative symptom factor 12.7 (5.6) -
PANSS positive symptom factor 16.9 (6.5) -

Note. EPP = Early Phase Psychosis, CPZ = chlorpromazine, PANSS =the Positive and Negative Syndrome Scale, BACS = Brief Assessment of Cognition in Schizophrenia.

**

p < .001.